title: A double-masked, placebo-controlled study of fluoxetine for hypochondriasis.
abstract: This study assessed the efficacy, durability, and tolerability of fluoxetine for hypochondriasis, a disorder for which controlled pharmacological trials are scarce. Fifty-seven patients with hypochondriasis were enrolled: 12 discontinued during the placebo run-in, and 45 were randomized to either fluoxetine or placebo for 12 weeks (acute treatment). Responder status was defined as a Clinical Global Impression rating for hypochondriasis of much or very much improved. Secondary outcome measures included severity of hypochondriasis, somatization, anxiety, and depression. Responders to acute treatment entered a 12-week maintenance phase to week 24. Sustained responders at week 24 entered a 12-week double-masked discontinuation phase. Primary analysis used the intent-to-treat sample. More patients responded with improvement in hypochondriasis when given fluoxetine compared with placebo, starting at week 8 (50.0% vs 19.0%, P = 0.03) and continuing to week 12 (62.5% vs 33.3%, P = 0.05). Mean dose at week 12 dose was 51.4 mg (SD, +/-23 mg). The acute treatment response was maintained to week 24 with more responders in the fluoxetine compared with the placebo group (54.2% vs 23.8%, P = 0.04). Significant improvement was not noted on the continuous secondary outcomes measures of hypochondriasis, with the exception of the Clinical Global Impression hypochondriasis severity scale at week 24. Likelihood of response was not associated with severity of psychiatric comorbidity. Durability of response after controlled drug discontinuation could not be reasonably assessed, given the small sample size of patients who entered the discontinuation phase (n = 10). Fluoxetine was well tolerated, with no significant differences in discontinuation due to side effects between treatment groups. Fluoxetine is a moderately effective and well-tolerated treatment for hypochondriasis.
authors.affiliation: New York State Psychiatric Institute, Manhattan, NY, USA.
authors.forename: Brian A
authors.initials: BA
authors.lastname: Fallon
authors.forename: Eva
authors.initials: E
authors.lastname: Petkova
authors.forename: Natalia
authors.initials: N
authors.lastname: Skritskaya
authors.forename: Arturo
authors.initials: A
authors.lastname: Sanchez-Lacay
authors.forename: Franklin
authors.initials: F
authors.lastname: Schneier
authors.forename: Donna
authors.initials: D
authors.lastname: Vermes
authors.forename: Jianfeng
authors.initials: J
authors.lastname: Cheng
authors.forename: Michael R
authors.initials: MR
authors.lastname: Liebowitz
mesh_terms: D000328:Adult; D000368:Aged; D003237:Connecticut; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D005260:Female; D005473:Fluoxetine / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D006998:Hypochondriasis / Q000188:drug therapy* / Q000523:psychology; D008297:Male; D008875:Middle Aged; D009518:New York; D010352:Patient Dropouts; D011569:Psychiatric Status Rating Scales; D017367:Selective Serotonin Reuptake Inhibitors / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D012720:Severity of Illness Index; D013997:Time Factors; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D005473:Fluoxetine; D017367:Selective Serotonin Reuptake Inhibitors